FREEOX BIOTECH
Based on the knowledge of oxidative stress and uric acid, Freeox Biotech is developing neuroprotective therapies to reduce the damage resulting from ischemia and in this way improve the recovery of the patients. Ox-01 is Uric Acid used as a medicinal product. Ox-01 has a proven effect in preventing the damage caused by reperfusion after stroke. Ox-02 Uricoline is a molecule resulting from the association of Ox-01 and Citicoline. Citicoline is an intermediate in the generation of phosphatidylcholine from choline.
FREEOX BIOTECH
Industry:
Biotechnology Health Care Neuroscience
Founded:
2017-03-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.freeoxbiotech.com
Total Employee:
1+
Status:
Active
Total Funding:
500 K EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API WordPress Font Awesome Wordpress Plugins Mobile Non Scaleable Content Euro PHP
Similar Organizations
Edison Pharmaceuticals
Edison Pharmaceuticals develops medicines for the treatments of children and adults diagnosed with rare and neglected diseases.
Impact Biomedicines
Impact Biomedicines is pioneering the development of life-changing treatments for patients.
Current Advisors List
Advisor
Advisor
Current Employees Featured
Ángel Honrado Funding Manager @ FreeOx Biotech
Funding Manager
Carlos Lurigados CEO @ FreeOx Biotech
CEO
Founder
Investors List
Montserrat Esteve
Montserrat Esteve investment in Seed Round - FreeOx Biotech
Javier Alsina
Javier Alsina investment in Seed Round - FreeOx Biotech
Official Site Inspections
http://www.freeoxbiotech.com
Unable to get host informations!!!
More informations about "FreeOx Biotech"
ABOUT - Freeox Biotech
Freeox Biotech is an innovative late-stage clinical company singularly focused on the discovery and development of Cerebrovascular Protective Therapeutics.See details»
FreeOx Biotech - Crunchbase Company Profile & Funding
Contact Email info@freeoxbiotech.com FreeOx Biotech is a pioneering late-stage clinical biotechnology company dedicated to transforming Acute Ischemic Stroke (AIS) management. …See details»
FreeOx Biotech - LinkedIn
FreeOx Biotech: Advancing Stroke Care through Innovation and Precision Medicine FreeOx Biotech is a pioneering late-stage clinical biotechnology company dedicated to transforming acute ischemic ...See details»
Freeox Biotech - 2025 Company Profile - Tracxn
Feb 28, 2025 Freeox Biotech - Developer of therapies for treating ischaemic stroke. Raised a total funding of $573K over 2 rounds from 4 investors. Founded by Angel Honrado in the year …See details»
Team - FreeOx
Emmett Phil Coriat. Chairman and CEO. 25+ years of experience in biotech/medtech as VC, founder, CEO of startups. Track record of successful dealmaking & exits.See details»
Freeox Biotech - Products, Competitors, Financials, Employees ...
Freeoxbiotech.com. Overview & Products; Financials; People; Founded Year 2017. Stage Seed | Alive. Total Raised $2.4M. Last Raised $1.83M | 1 yr ago. About Freeox Biotech. Freeox …See details»
FreeOx Biotech Company Information - Funding, Investors, and More
Website: https://freeoxbiotech.com; Company size: 1 - 11 employees Headquarters: Barcelona, Spain Founded: 2017 Social accounts: Twitter Linkedin; Funding. Funding series. Funding …See details»
Freeox Biotech - VentureRadar
"Freeox Biotech is an innovative company born to discover and develop medicines addressed to reduce the effects of the oxidative stress in the organism, and especially those related to the …See details»
FreeOx 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for FreeOx. Use the PitchBook Platform to explore the full profile.See details»
FreeOx Biotech SL - Drug pipelines, Patents, Clinical trials - Synapse
Explore FreeOx Biotech SL with its drug pipeline, therapeutic area, technology platform, 1 news, Disease Domain:Nervous System Diseases, Technology Platform:Small molecule drug, …See details»
FreeOx Biotech Overview | SignalHire Company Profile
FreeOx Biotech is a private company that has been in the industry for 6 years. The company currently specializes in the Biotechnology, Medical Research & Laboratories, Biotechnology …See details»
Freeox Biotech - Craft
Freeox Biotech has 5 employees at their 1 location and $572.84 k in total funding,. See insights on Freeox Biotech including office locations, competitors, revenue, financials, executives, …See details»
FreeOx Biotech Celebrates Landmark 2024 with Record Growth: …
Innovative Biotech Company Expands Executive Team with Three C-Suite Appointments and Advances Pipeline with Key Trial Evaluations. BARCELONA and PALO ALTO, Feb. 13, 2025 …See details»
FreeOx Biotech - Overview, News & Similar companies - ZoomInfo
Nov 15, 2023 FreeOx Biotech Formally Launches Seed Round to Fund Phase III Pivotal Trial Planned Phase III for Ox-01 to Begin in AIS in Early 2025 • Pivotal Trial to Evaluate Novel …See details»
Freeox Biotech - VentureRadar
Freeox Biotech is an innovative company born to discover and develop medicines addressed to reduce the effects of the oxidative stress in the... ... Find out more ...See details»
FreeOx Biotech Formally Launches Seed Round to Fund Phase III …
Dec 5, 2023 Planned Phase III for Ox-01 to Begin in AIS in Early 2025 Pivotal Trial to Evaluate Novel Adjunct Drug for Mechanical Thrombectomy. FreeOx Biotech SL, a late-stage clinical …See details»
FreeOx Biotech lead asset recommended by NIH/NINDS SPAN …
Nov 16, 2023 FreeOx Biotech lead asset recommended by NIH/NINDS SPAN network for further development. FreeOx Biotech Adds Leadership for Advancing Ox-01 to Phase III and …See details»
FreeOx Biotech Formally Launches Seed Round to Fund Phase III
Dec 5, 2023 Planned Phase III for Ox-01 to Begin in AIS in Early 2025 • Pivotal Trial to Evaluate Novel Adjunct Drug for Mechanical Thrombectomy. BARCELONA, Spain, Dec. 5, 2023 …See details»
News - FreeOx
Mar 4, 2025 FreeOx Biotech FreeOx's Ox-01 Outperforms 3 Candidates from Big Pharma; Phase 2/3 Expected to Initiate in 2025 BARCELONA / PALO ALTO, Spain, Nov. 15, 2024 …See details»